Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kamada ( (IL:KMDA) ) has issued an announcement.
Kamada Ltd., a global biopharmaceutical maker of specialty plasma-derived therapies, has clarified Israeli withholding tax procedures for a previously declared cash dividend of $0.25 per share, totaling about $14.4 million, announced on March 11, 2026 and scheduled for payment on April 7, 2026 to shareholders of record as of March 23, 2026. Following a tax ruling from the Israel Tax Authority, eligible Nasdaq-listed shareholders resident in tax-treaty countries may obtain reduced Israeli withholding rates or exemptions via a designated tax agent, but must submit detailed residency and ownership documentation by May 9, 2026, shaping the net cash they ultimately receive and underscoring the complexity of cross-border dividend taxation for investors.
The most recent analyst rating on (IL:KMDA) stock is a Buy with a ILs3049.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies and a portfolio of marketed products targeting rare and serious conditions. The company, whose controlling shareholder is Israel’s FIMI Opportunity Funds with about 38% of its ordinary shares, is listed on Nasdaq and the Tel Aviv Stock Exchange and focuses its strategy on driving profitable growth in niche therapeutics.
Average Trading Volume: 86,173
Technical Sentiment Signal: Strong Buy
Current Market Cap: ILs1.46B
See more data about KMDA stock on TipRanks’ Stock Analysis page.